Overview

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Epratuzumab